UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 18, 2008
______________
Stellar Pharmaceuticals Inc.
(Exact name of registrant as specified in charter)
______________
Ontario, Canada | 0-31198 | Not Applicable |
(State or other jurisdiction of incorporation) | (Commission | (IRS Employer Identification No.) |
544 Egerton Street, London, Ontario, Canada, N5W 3Z8
(Address of principal executive offices)
(519) 434-1540
(Registrant’s Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Events.
On August 18, 2008, Stellar Pharmaceuticals Inc. (the "Company") issued a press release announcing the successful completion of Watson's Pilot Clinical Study
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits
Exhibit No. |
| Description |
| Stellar Pharmaceuticals Inc. Announces Successful Completion Of Watson’s Pilot |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Stellar Pharmaceuticals Inc. | |
|
|
|
|
|
|
Date: August 18, 2008 | By: | /s/Peter Riehl |
|
| Peter Riehl |
|
| President and Chief Executive Officer |
3